GlassScriptPhysician profile
Amber Haq
NPI 1033649900
$2,906.38
in general payments reported to CMS, 2019-2025
19 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $262 · 2023: $742 · 2024: $1,156 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,107.53 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $558.62 | 2022-2025 | |
| Boston Scientific Corporation | $265.03 | 2021-2022 | |
| Amgen INC. | $172.21 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.25 | 2023-2024 | Jardiance, Ofev |
| Alnylam Pharmaceuticals INC. | $122.83 | 2023 | Amvuttra |
| Edwards Lifesciences Corporation | $96.47 | 2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $79.58 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.68 | 2022-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $52.12 | 2023-2024 | Arexvy, Shingrix |
| Dynavax Technologies Corporation | $51.17 | 2024 | Heplisav-B |
| Pfizer INC. | $41.55 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $41.37 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $26.11 | 2025 | |
| Renalytix Ai, INC. | $23.85 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.15 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $19.36 | 2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $18.04 | 2022 | |
| Corcept Therapeutics | $14.46 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.